Inhibitor Therapeutics

Company snapshot

INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders. SUBA-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, w

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Inhibitor Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Inhibitor Therapeutics.

1. Jun 8, 2026 Clinical update

   Window of Implantation — Unknown

2. Jun 8, 2026 Clinical update

   Small RNA sequencing — Phase 1

3. Mar 19, 2024 Patent grant

   Compositions for treating heart disease by inhibiting the action of mAKAP-β

4. Jan 25, 2022 Patent grant

   Compositions for treating heart disease by inhibiting the action of mAKAPβ

5. Apr 14, 2020 Patent grant

   Compositions for treating heart disease by inhibiting the action of mAKAP-β

View all clinical trial activity →

• What is Inhibitor Therapeutics?

  INHIBITOR Therapeutics is a pharma organization headquartered in Tampa, USA. It trades on NYSE under ticker INTI. Primary therapeutic focus areas include Fertility. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 5 patent record(s) to this entity from public FD

• Is Inhibitor Therapeutics publicly traded?

  Yes. Inhibitor Therapeutics is listed with ticker INTI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Inhibitor Therapeutics develop or market?

  We link 2 drug profile(s) where Inhibitor Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/inhibitor-therapeutics#company-drugs.

• What are the latest developments for Inhibitor Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Inhibitor Therapeutics focus on?

  Inhibitor Therapeutics focuses on Fertility based on our analysis of their pipeline programs and drug development activities.